Find clinical trials for triple negative breast cancer. Search for triple negative breast cancer clinical trials in different cities and states across the United States.
Filter
1
Filter results
Results: 155
Active & Responsive
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
for
Leptomeningeal Disease, Triple Negative Breast Cancer,
Location: 1 recruiting location
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sex: All
Age: 18+
Code: NCT05809752
Phase1, Recruiting
Active & Responsive
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
for
Solid Tumor, Adult, Colorectal Cancer,
Location: 13 recruiting locations
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT04981119
Recruiting
Active & Responsive
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
for
Triple Negative Breast Cancer (TNBC),
Location: 9 recruiting locations
Sponsor: Boundless Bio
Sex: All
Age: 18+
Code: NCT05827614
Phase1, Recruiting
Active & Responsive
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
for
Non-Small Cell Lung Cancer, Renal Cell Carcinoma,
Location: 18 recruiting locations
Sponsor: Janux Therapeutics
Sex: All
Age: 18 - 70+
Code: NCT05783622
Phase1, Recruiting
Active & Responsive
Study of Screening Brain MRIs in Stage IV Breast Cancer
for
Triple Negative Breast Cancer, HER2-positive Breast Cancer,
Location: 1 recruiting location
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sex: All
Age: 18+
Code: NCT05115474
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
for
Triple Negative Breast Cancer
Location: 1 recruiting location
Sponsor: Medical University of South Carolina
Sex: All
Age: 18+
Code: NCT06845319
Phase2, Recruiting
Active & Responsive
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
for
Triple Negative Breast Cancer, HER2-negative Breast Cancer,
Location: 10 recruiting locations
Sponsor: Dren Bio
Sex: All
Age: 18+
Code: NCT06999187
Phase1, Recruiting
Active & Responsive
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
for
Triple Negative Breast Cancer
Location: 2 recruiting locations
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sex: All
Age: 18+
Code: NCT05528133
Phase2, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)